^
Association details:
| Biomarker: | EGFR G719X + EGFR L861Q + EGFR S768I |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Ameile (aumolertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
373P - Safety and efficacy of aumolertinib treatment in patients with advanced NSCLC harboring uncommon EGFR mutations: Cohort 2
Published date:
11/28/2022
Excerpt:
We aim to explore the efficacy and safety of third-generation TKI Aumolertinib in EGFR-uncommon mutant NSCLC pts....Aumolertinib in G719X&L861Q&S768I genotypes showed better outcome compared to other genotypes.
Trial ID:
